Enphase Energy Inc vs Globus Medical Inc. Class A Common Stock — how do they compare? Enphase Energy Inc trades at $28.81 (market cap $4.23B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.4× Enphase Energy Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| ENPH | GMED | |
|---|---|---|
Market Cap | $4.23B | $10.25B |
Volume | 4,755,897 | 1,108,124 |
Sector | Energy | Health |
52-Week High | $72.33 | $96.82 |
52-Week Low | $26.12 | $58.33 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $9.76B |
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $29.35, down 6.8% in the last session, reflecting recent volatility amid broader solar sector pressures. The stock shows a bearish technical signal with key support at $29. Valuation ratios like a P/E of 31.71 and P/S of 3.22 suggest a premium, while recent quarters saw mixed earnings with two misses. Positive developments include utility approvals for its IQ Meter Collar and advancements in solid-state transformer technology for AI data centers.
The outlook is cautious; while analyst consensus targets $43.18 implying upside, high borrowing costs and competitive risks weigh on solar stocks. Revenue declined from 2023's $2.3B to $1.47B in 2025, though net margins improved. Investors should balance growth potential in energy tech against execution risks and market sentiment shifts.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →